hSTC810 for Solid Tumors
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called hSTC810 in patients with advanced solid tumors. The study will check if the drug is safe, how well patients can tolerate it, and how it behaves in the body. Researchers will also look at early signs of how effective the drug might be.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications, but you cannot have received anti-cancer treatment, radiotherapy, or major surgery within 4 weeks before starting the study. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the treatment hSTC810 for solid tumors?
Research suggests that targeting butyrophilin proteins, like those in hSTC810, can help the immune system attack cancer cells more effectively by enhancing the activity of certain immune cells (T cells) against tumors. This approach has shown promise in improving survival in various cancer models.12345
What safety data exists for bispecific antibodies like hSTC810 in humans?
Bispecific antibodies, like hSTC810, have been associated with side effects such as cytokine release syndrome (a condition where the immune system releases too many proteins into the blood too quickly) and infections, which are common during treatment. Early intervention with medications like tocilizumab can prevent severe symptoms, and monitoring for infections is important. Other side effects may include skin and nail disorders and loss of taste, depending on the specific target of the antibody.678910
What makes the drug hSTC810 unique for treating solid tumors?
hSTC810 is a bispecific antibody, which means it can bind to two different targets at once, potentially enhancing its ability to direct the immune system to attack cancer cells. This approach is similar to other bispecific antibodies used in blood cancers, but its application in solid tumors is novel, offering a new strategy for targeting these types of cancers.910111213
Research Team
Medical director
Principal Investigator
STCube, Inc.
Eligibility Criteria
This trial is for adults with advanced solid tumors who have a life expectancy of at least 12 weeks, can consent to the study, and agree to use contraception. They must have at least one measurable tumor and be in good physical condition (ECOG PS ≤1). People with active brain metastases, recent cancer treatments or major surgeries, certain infections like hepatitis or COVID-19, autoimmune diseases needing treatment within 2 years, severe allergies to checkpoint inhibitors, or serious heart conditions cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose-escalation
Participants receive escalating doses of hSTC810 to evaluate safety, tolerability, and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for overall survival and other long-term outcomes
Treatment Details
Interventions
- hSTC810
Find a Clinic Near You
Who Is Running the Clinical Trial?
STCube, Inc.
Lead Sponsor